Jobs was not talking about hospitals, clinical workflow, artificial intelligence or digital health. He was talking about where innovation must begin, not with technology, but with customer experience.

His point was simple and demanding. You cannot start with the technology and then figure out where to sell it. You have to start with the experience you want people to have, then work backward to the technology, systems and decisions required to make that experience possible.

That lesson belongs at the center of health innovation.

Too many promising companies enter the health sector leading with sophisticated platforms, powerful algorithms, elegant data architecture or novel science. Those strengths matter. However, they are not where adoption begins. Adoption begins with the people expected to use, believe in, approve, pay for, or benefit from the solution.

For health-sector entrepreneurs, the starting question cannot be, “What can our technology do?” It has to be, “What experience are we trying to create for the patient, clinician, researcher, administrator or institution we seek to serve?”

This is becoming increasingly visible as digital tools converge with therapeutics and clinical trials become more dependent on digital solutions. The question is no longer only whether the technology works. It is whether the experience works for patients, clinicians, researchers and institutions.

That is where entrepreneurial friction in health begins: not as an obstacle to creativity, but as a test of whether innovation has been shaped by the needs of the people who must use, have confidence and adopt it or by the capabilities of the technology itself.

From Fragmentation to Friction

For years, I have written about fragmentation throughout health. Long before fragmentation became a common buzzword at conferences or board meetings, it was evident that disconnected systems, competing incentives and isolated decision-making were creating unnecessary barriers for patients and clinicians alike. Fragmentation described the architecture of the problem.

Increasingly, I believe friction better describes the human experience of that architecture.

Fragmentation explains why organizations struggle to work together. Friction explains what physicians experience when they document the same information repeatedly, what nurses experience when technology disrupts rather than supports their workflow, what patients encounter when they navigate disconnected systems and what entrepreneurs discover when promising innovations stall within institutional bureaucracy.

Health professionals know this concern well from years of implementing electronic medical records. Too often, technology introduced to organize care has added clicks, documentation burden, and screen time, reminding innovators that adoption depends not only on what a system can do, but also on what it asks clinicians to absorb.

Every unnecessary approval, incompatible technology platform, duplicate workflow, unclear responsibility and poorly communicated decision creates resistance. None of those obstacles improve patient care. Each one slows the movement of innovation from discovery to implementation.

Health does not suffer from a shortage of remarkable ideas. Every week brings advances in artificial intelligence, biotechnology, precision medicine, diagnostics and digital health. Many of these innovations demonstrate meaningful improvements in clinical outcomes. Far fewer become part of everyday practice because the institutional friction surrounding implementation often receives less attention than the science itself.

Communication is a Key Implementation Strategy

Many founders in health start-ups are rightly fluent in science, engineering, data and clinical logic. That expertise is essential. The risk is that the human pathway to use receives less attention: the relationships, explanations and confidence-building that help patients, clinicians, administrators, payers and institutions understand how a new solution fits into their world. Without that connection, even strong ideas can meet resistance that looks like reluctance but often reflects an avoidable gap in understanding.

One misconception continues to undermine otherwise promising innovation. Communication is often viewed as beginning only after the product is complete. Marketing launches the announcement. Public relations introduces and positions innovation. Internal communications explain the rollout. That sequence misunderstands the purpose and impact of communication.

Communication is not simply how organizations describe innovation. Communication helps institutions understand change, reduce uncertainty and build the confidence required for adoption. It belongs alongside engineering, clinical research, workflow design and implementation planning from the earliest stages of development.

Consider a company that develops an artificial intelligence platform capable of reducing radiology turnaround times while maintaining strong clinical accuracy. The evidence is compelling. Independent validation supports the findings. Investors celebrate the technology’s potential.

Implementation nevertheless slows because department leaders worry about governance, radiologists question liability, information technology teams raise cybersecurity concerns and administrators remain uncertain about workflow integration. None of those questions challenge the supporting science. Each reflects uncertainty that could have been anticipated and addressed much earlier through supporting evidence and communication.

Consider another example. A digital platform helps people living with diabetes remain engaged between office visits, improving adherence and strengthening patient self-management. Physicians initially hesitate because they worry the technology will dramatically increase after-hours patient messages. Once the implementation team demonstrates automated triage, clearly defined clinical responsibilities and realistic workflow expectations, enthusiasm begins to replace skepticism. The technology itself remains unchanged. Understanding changes, interest grows and institutional friction begins to ease.

Communication does not replace implementation. It is part of the implementation. It turns complexity into shared understanding, aligns the people who must approve, use, pay for change, and reduces the friction that market fragmentation creates. Without communication, even beneficial innovation can remain trapped between promise and practice.

Designing Innovation for the Real World Experience

Jobs’ lesson should not be reduced to a technology slogan. It is honed and relentless discipline. Start with the experience and work backward. Keep asking whether each decision brings the user closer to value or pushes the organization deeper into layers of complexity. As Stephen R. Covey advised, “begin with the end in mind.” In health innovation, that end is not the technology itself. It is the experience, confidence and value created for the people expected to embrace and engage.

Health entrepreneurs should apply that relentless discipline within their own organizations by encouraging healthy debate among engineers, clinicians, patients, operational leaders and communicators. Diverse perspectives almost always produce stronger solutions because they test assumptions before the market, hospital, physician, or patient is forced to do so.

Equal attention should be devoted to eliminating the destructive friction that appears once innovation enters health institutions. Entrepreneurs should ask how many additional clicks a physician must complete, how many approvals a hospital must obtain, how easily the innovation integrates with existing systems, and whether every stakeholder understands not only what the innovation accomplishes but also how it improves everyday practice.

That is why one experienced health innovation champion, Levi Shapiro, founder and curator of mHealth Israel, a community of more than 20,000 health entrepreneurs, frames the challenge this way: “Clinical results and physician enthusiasm are table stakes. To overcome the ‘death by PILOT’ trap, the technology should integrate seamlessly into existing workflows, harmonize with operational and security requirements and demonstrate measurable ROI with minimal oversight. The technologies that scale are usually the ones that make adoption feel manageable, not disruptive.”

The future of health innovation will not be defined solely by better algorithms, more sophisticated diagnostics or increasingly powerful therapeutics. Success will belong to organizations that recognize implementation as a discipline requiring leadership, operational design, communication and empathy. Scientific excellence opens the door. Institutional readiness determines whether anyone walks through it.

Some friction strengthens thinking and encourages excellence. Other friction creates delay, confusion and unnecessary resistance. Recognizing the difference may become one of the most important responsibilities facing health entrepreneurs, institutional leaders and communicators alike.

Health does not face an innovation deficit. It faces an implementation deficit, made worse when communication is treated as an afterthought. Reducing the friction between what technology can do and what people need to experience may prove to be the next great breakthrough.

The post The Friction Between Innovation and Experience appeared first on Medika Life.

But this year, because of a new Medicare program, Curry has traveled a little more often.

In February, during one trip, he was told unexpectedly that he needed preapproval for the procedure. Then he went again a month or so later to get the injection, for a total of 10 hours on the road. His clinic wanted him to come in a third time, which they had never asked of him before. That appointment was “just to fill out a piece of paper to tell them how you feel again,” Curry said, so he hasn’t gone.

In January, Oklahoma became one of six states to begin a pilot program testing the use of preapprovals in traditional Medicare, the federal health insurance program for people 65 and older or with disabilities. Medicare had previously eschewed the practice — also known as prior authorization — which requires patients or someone on their medical team to seek insurance approval before proceeding with certain procedures, tests, and prescriptions.

Epidurals like Curry’s are among 13 medical services subject to the new program because the Trump administration says they’re prone to fraud or misuse. Powered by artificial intelligence, the program — called the Wasteful and Inappropriate Service Reduction Model, or WISeR — is intended to save the federal government money and protect patients from potentially unsafe or unneeded care.

Yet early reviews from Oklahoma and the other pilot states — Arizona, New Jersey, Ohio, Texas, and Washington — suggest WISeR’s rollout has not been smooth. Patients, doctors, and other healthcare professionals who spoke with KFF Health News say the effort has created confusion, errors, long wait times, and stress. Some described the rollout as “horrendous” and say people enrolled in Medicare in the pilot states are now getting ensnared in the same red tape as those with private insurance.

One key concern is that it all happened too hastily. WISeR was announced in June 2025 and launched in mid-January.

That was “quicker than normal” for the federal government, said Todd Baker, who recently stepped down as CEO of the Ohio State Medical Association. Doctors “just sort of had to figure it out,” added Jeb Shepard, director of policy at the Washington State Medical Association.

Government contractors have also acknowledged the rapid pace. “We’ve had an aggressive rollout from the time of being notified to going live,” said Jeremy Friese, CEO of Humata Health, the vendor for Oklahoma. Tech executives servicing other states have said they were still adding features to their products in the spring.

Abe Sutton, director of the Center for Medicare and Medicaid Innovation, which is administering the program, didn’t comment on the rollout schedule. But he said in a statement that the goal of these reforms is to ensure that prior authorization is efficient, fast, and streamlined.

“The model aims to reduce inappropriate care without delaying appropriate care,” he said.

Mehmet Oz, the leader of the Centers for Medicare & Medicaid Services, told NewsNation in December that they were “rolling out some prior authorization on abused practices.”

“The purpose of these is not to deny care,” Oz continued. “It’s to make sure you get the care you need and deserve, not the care some unscrupulous doctor wants to use on you.”

Medicare has struggled in recent years with suspected fraud associated with particular services. The Department of Health and Human Services’ inspector general warned in September that the program’s spending on skin substitutes, for example, had surged nearly 700% over two years, raising “major concerns about fraud, waste, and abuse.” Skin substitutes are among the 13 therapies currently subject to review under WISeR.

The program also imposes prior authorization requirements for kyphoplasty, a surgery for spinal fractures, which a report by the Medicare Payment Advisory Commission flagged as overused.

Sutton acknowledged, however, that “the percentage of providers committing waste, fraud, and abuse is small.”

Consumers and clinicians largely detest prior authorization. Even as federal health officials test the process for Medicare, the Trump administration is trying to scale it back for those with private insurance. According to a KFF poll conducted in January, 69% of insured adults consider prior authorization a burden for care.

Through WISeR, doctors and their staff log in to online portals to submit medical records that justify the procedures. Using artificial intelligence, the systems quickly approve applications that meet the program’s criteria, Friese, Humata’s chief executive, told KFF Health News. He said there is an “immediate yes” in 88% of cases for which clinical data supports an approval.

CMS has touted the process as one in which decisions are returned within 72 hours. After that, clinicians receive a “universal tracking number,” which allows them to schedule the procedure and get paid. In practice, however, participants say the process is anything but easy.

The University of Washington’s medical system alone had nearly 100 patients waiting earlier this year for epidural injections due to WISeR-related delays, according to an April report from the office of U.S. Sen. Maria Cantwell (D-Wash.) that drew on hospital association data. “Now, patients are subject to delays or denials which did not exist prior to the WISeR Model,” the report said.

Curry, the Oklahoma cattle farmer, said he might go to Kansas for future treatments to avoid the approval process. Dorota Gribbin, a New Jersey-based physical medicine and rehabilitation physician, said that by the time authorization came for one of her patients who needed a back pain procedure, the patient had gone to the hospital for more expensive care.

Jennifer Valle, a precertification and insurance supervisor at Clinical Radiology of Oklahoma, said when it comes to kyphoplasties, there has been a lot of “nitpicking” from reviewers. Other times, information her practice provides to CMS gets overlooked, she said, and reviewers ask for imaging that’s already in the file.

Claims with no problems are supposed to be paid within 15 days, said James Webb, a musculoskeletal radiologist in Tulsa, Oklahoma, who has also been frustrated by the prior approval and reimbursement process for kyphoplasties. “Six- to eight-week delays is what we’ve been seeing,” he said.

“It’s been horrendous,” said Jerry Sobel, a Phoenix-area pain management doctor. “Right from the beginning, there seemed to be no organization.” Sobel said that as of May, he hadn’t gotten paid by Medicare for nine epidurals.

“We continuously monitor operations and work closely with stakeholders to address questions and improve the provider experience,” said Sundar Subramanian, the CEO of Zyter, which has the contract for Arizona.

During an April webinar, another Zyter executive acknowledged a large backlog in payments stretching to January. Those backlogs “are currently being resolved,” Medicare’s Sutton said, without providing further detail.

When asked about other issues — including what doctors suspect are AI-driven errors — Medicare’s Sutton said the agency appreciates “feedback on provider experience.” It will be used “to help providers better understand WISeR processes,” he said.

Although CMS vendors say humans make the final decisions on approvals, doctors and their staffs believe artificial intelligence is playing a large role in the process and that denials are sometimes the result of AI hallucinations that garble or make up information.

One Arizona doctor, who wasn’t authorized by his practice to speak, recalled a denial saying his patient wasn’t eligible for procedures in the thoracic region, or mid-back. The patient needed an injection to the neck. Webb, the Oklahoma radiologist, documented four times that a patient lacked numbness, and yet his WISeR application was still denied, citing numbness, which, in the reviewer’s interpretation, would rule out the spinal surgery procedure.

Friese, Humata’s CEO, said he hasn’t heard about any AI hallucinations.

The process is also raising government costs. With more rejections, more appeals are being filed with Medicare’s administrative contractors. The government pays the contractors to handle the appeals, and Medicare’s Sutton acknowledged that the agency has “accounted for potential changes in the volume of Medicare appeals because of the WISeR program and its associated costs.”

Eighty-four percent of commercial insurers already use AI tools, according to a survey released in 2025 by the National Association of Insurance Commissioners, though they have consistently said AI isn’t used to deny prior authorization requests.

Its use in Medicare risks introducing friction and frustration into the program — and piling costs onto its beneficiaries. Prior authorization saves money for insurers partly by making patients pay a price in wait times and inconvenience, said Miranda Yaver, a University of Pittsburgh health policy researcher studying the technique.

“People will end up getting ensnared in a lot of red tape, having to be on hold, and getting rerouted,” she said. She often wonders whether prior authorization simply shifts costs to patients and doctors, rather than saving them.

Some doctors involved in Medicare’s prior authorization experiment believe it will inevitably expand beyond a few services officials in Washington consider fraud-prone.

“Everybody knows that if this pilot project works, it will be prior auth for basically all procedures,” said Mary Clarke, a family practice physician in Stillwater, Oklahoma. “If they can show that they can save money, then that’s going to be extrapolated and rolled out to other procedures and multiple other things in other states.”

When asked whether CMS is considering expansion of its prior authorization pilot, Sutton said in his statement that there are “currently no changes” considered for the list of services subject to the WISeR program, “but CMS continues to assess whether any changes are warranted.”

The post Medicare’s AI Push Snarls Patients and Doctors in Errors and Delays appeared first on Medika Life.

What Is Misophonia, Exactly?

The word misophonia comes from the Greek for “hatred of sound.” But that description sells it short. It isn’t simply an aversion to noise. It’s a disorder in which specific sounds, usually soft, repetitive, and made by another person, set off an intense chain reaction in the body and mind. Researchers define it as a condition characterized by strong emotional, physiological, and behavioral responses to sounds that most people barely notice.

The most common triggers include chewing, swallowing, lip smacking, slurping, throat clearing, sniffling, and breathing. Tapping on a keyboard, pen clicking, and the crinkle of a wrapper can also set it off. Some people also react to visual cues, such as watching someone’s jaw move, even without sound.

Estimates of how many people have misophonia vary, but multiple studies suggest that between 5% and 20% of the population experience symptoms significant enough to interfere with daily life. It often starts in childhood or early adolescence, with an average onset around age 12 to 13. It can persist for decades if left unaddressed.

What’s Happening in the Brain?

For a long time, people assumed this was a personality quirk or a sign of anxiety. New brain imaging research tells a very different story.

A landmark study published in Human Brain Mapping in early 2026 examined brain scans from 939 adults and found a specific connectivity disruption unique to misophonia. The culprit is a brain region called the anterior insula, a hub of the brain’s salience network. This is the area that decides, in a fraction of a second, what information deserves your full attention. In people with misophonia, the connection between the auditory cortex and the anterior insula is wired differently. The brain flags trigger sounds as urgent threats before the person has any chance to think about it.

Critically, this pattern did not appear in people with anxiety, depression, or autism, even when researchers analyzed the same brain data. It appears to be a misophonia-specific neural signature. That distinction matters enormously for treatment.

Earlier fMRI research confirmed that when a person with misophonia hears a trigger sound, specific regions fire up fast: the right insula, the anterior cingulate cortex, and the superior temporal cortex. Heart rate increases. Skin conductance rises. The emotional response arrives before reasoning can step in. This is why telling someone with misophonia to “just ignore it” is about as useful as telling someone with a broken leg to walk it off.

Research presented at the 2025 Misophonia Collaborative Forum added another dimension. Brain regions that become overactive during trigger exposure respond similarly whether a person is actually hearing the sound, watching a silent video of it, or simply imagining it. This tells us that misophonia isn’t purely a hearing problem. It involves memory, expectation, and mental imagery, too.

More Than Irritation: The Emotional and Physical Toll

The emotional range that people with misophonia report goes well beyond irritation. Anger is the most common reaction, but disgust, anxiety, panic, and even shame are also common. Physically, people describe muscle tension, sweating, nausea, a tightened chest, and a racing heart. The urge to flee the situation can feel overwhelming.

The source of the sound matters significantly. Research published in 2025 confirmed that sounds made by other people, especially people the listener knows, produce far stronger reactions than the same sounds made by strangers or machines. This is why family dinners can become unbearable war zones, while the same sounds in a crowded restaurant cause far less distress. It’s personal in the most literal neurological sense.

Research also finds that trigger sounds interfere with a person’s ability to concentrate on what they’re doing. People with misophonia are measurably worse at staying on task when triggers are present. Over time, the condition leads many people to avoid shared meals, open offices, public spaces, and sometimes their own families. The social and professional consequences can be severe.

Who Gets Misophonia?

Misophonia shows up across populations, but some groups appear more vulnerable. A 2025 systematic review found that between 12.8% and 35.5% of autistic people experience it, with 79% of those individuals also having anxiety, OCD, or other sensory sensitivities. It also appears frequently alongside mood disorders and obsessive-compulsive disorder in the general population.

Misophonia is not currently listed as a stand-alone diagnosis in the DSM-5 or ICD-11. But the field is moving toward formal recognition. In 2022, a consensus definition was published for the first time. Since then, standardized assessment tools have been developed, prevalence studies have grown in size and rigor, and clinical trials have finally begun.

What Can Actually Help?

Good news arrived in 2026 in the form of the field’s first randomized controlled trials, meaning research with a real comparison group and rigorous standards. Two studies confirmed that specific forms of therapy produce meaningful reductions in misophonia symptoms.

Cognitive behavioral therapy, or CBT, remains the most studied approach. A 2025 review presented at the World Tinnitus Congress confirmed that CBT delivered by both psychologists and audiologists significantly reduces the impact of misophonia on quality of life. Online CBT programs also show positive results, though dropout rates are higher than with face-to-face treatment.

Acceptance and commitment therapy, or ACT, also showed strong results in 2026 trials. ACT doesn’t try to eliminate the emotional response. Instead, it teaches people to tolerate distress without letting it control their behavior. For misophonia, this can mean staying at the dinner table, completing a workday in a shared office, or staying present in a relationship that might otherwise be derailed by triggers.

On the technology front, researchers at Duke University’s Center for Misophonia and Emotion Regulation are collaborating with a team at the University of Washington to develop a sound-suppression platform that uses headphones and an app. The goal is to allow a person to select which specific sounds they want filtered out while still hearing everything else.

Perhaps the most exciting frontier is neurostimulation. Clinical trials are underway to test whether transcranial magnetic stimulation, which uses magnetic pulses directed at specific brain regions, can calm the misfiring salience network at its source. If successful, this approach would be the first to directly target the underlying brain mechanism rather than managing its downstream effects.

You’re Not Alone, and You’re Not Broken

If any of this sounds familiar, the most important thing to know is that misophonia is real, it’s measurable, and it isn’t a personal failure. It also isn’t a life sentence. With the right support, people can and do find ways to manage their reactions, protect their relationships, and reclaim spaces that triggers have stolen from them.

Science has only recently begun to take misophonia seriously. The brain imaging findings of 2026 that show a disorder-specific neural signature are exactly the kind of evidence that turns skeptics into allies and moves conditions from the margins of medicine to its center. That shift is happening now.

Talk to a psychologist or psychiatrist who is familiar with sensory processing disorders. Be honest about what triggers you, how strongly, and how much it costs you in daily life. You deserve a professional who takes this seriously, because the science finally does.

The post That Sound Is Making Me Snap appeared first on Medika Life.

Its leaders were visible throughout the convention, participating in discussions on biopharma innovation, precision medicine, artificial intelligence, investment, genomics and policy. Partnership announcements emerged throughout the week. Delegations moved between panel discussions and private meetings with investors, entrepreneurs, researchers, and industry leaders. The message was clear. Abu Dhabi is making a strategic effort to become a notable player in biotechnology and the life sciences.

The timing is not accidental.

Around the world, governments increasingly view biotechnology as a strategic investment industry. Scientific innovation drives economic growth. Advanced therapeutics create new manufacturing opportunities. Genomics and precision medicine are reshaping approaches to disease prevention and treatment. Nations that attract talent, investment and scientific expertise position themselves at the forefront of one of the century’s most consequential industries and life-sustaining movements.

Abu Dhabi is determined to be among those countries.

Building the Innovation Foundation

Substantial investments and partnerships in infrastructure, research, education and health innovation support the Emirate’s ambitions.

In April 2025, Abu Dhabi launched the Health, Endurance, Longevity and Medicine (HELM) Cluster, an initiative designed to establish a globally competitive ecosystem spanning biotechnology, pharmaceuticals, medical technology, genomics, digital health, artificial intelligence and advanced manufacturing.

Officials project the initiative will contribute AED 94 billion to the economy by 2045, attract more than AED 42 billion in investment and create approximately 30,000 jobs.

Those figures reflect more than economic development goals. They signal a growing recognition that biotechnology is a cornerstone of future growth and global competitiveness.

The Emirate is not starting from scratch. Organizations including M42, PureHealth, Mubadala Bio, Khalifa University, and the Mohamed bin Zayed University of Artificial Intelligence have established a foundation that combines research, clinical capabilities, advanced analytics and investment resources. The UAE Genome Program has surpassed 900,000 sequenced genomes, making it one of the world’s largest population genomics initiatives and providing a valuable resource for scientific research and precision medicine.

These investments provide the ingredients necessary to compete. Partnerships provide the opportunity to accelerate progress.

Building Through Collaboration

Biotechnology has long been a collaborative enterprise among private equity and entrepreneurs, academic medicine and corporations, and, now, nations working side by side with other countries’ governments.

Scientific discovery depends on the exchange of knowledge among researchers, entrepreneurs, clinicians, manufacturers, regulators, and investors. No single country possesses every advantage. Successful ecosystems learn how to connect their strengths with those of others.

Abu Dhabi’s recent actions suggest its leaders understand this reality more than anyone else. They act on it.

During the BIO International Convention, the Department of Health – Abu Dhabi announced a strategic collaboration with Sanofi focused on vaccine development and life sciences innovation. The previous year at BIO in Boston, the Department established a partnership with Boehringer Ingelheim that expanded access to the company’s OpnME research platform, creating new opportunities for translational research and scientific discovery.

An additional 2025 agreement was signed with Abbott, focused on pharmaceutical innovation, manufacturing capabilities, and emerging technologies.

These were not isolated announcements. They represented a broader effort to connect Abu Dhabi with leaders across the global life sciences community. That strategy continued at BIO 2026.

On June 23, 2026, the Department of Health – Abu Dhabi announced a strategic partnership with Biocom California, one of the world’s largest life sciences associations representing more than 1,800 biotechnology, pharmaceutical, and medical technology organizations. The agreement creates a formal gateway between the California innovation ecosystem and Abu Dhabi’s growing life sciences sector, strengthening opportunities for collaboration among researchers, entrepreneurs, investors, and innovators across both markets.

The significance of the announcement extends beyond California. It reflects Abu Dhabi’s effort to connect itself to some of the world’s most influential innovation networks and to participate in the exchange of scientific knowledge, talent, and investment that increasingly defines biotechnology leadership.

Moving Up the Biotech Value Chain

If the Biocom agreement demonstrated Abu Dhabi’s commitment to global collaboration, a second announcement made the Emirate’s ambitions even clearer.

On June 24, 2026, the Department of Health – Abu Dhabi, M42, and Mammoth Biosciences announced a partnership to advance gene-editing therapies, clinical research, and advanced therapy manufacturing in Abu Dhabi. The agreement seeks to leverage insights generated through the Emirati Genome Program while supporting the development of next-generation treatments for inherited diseases.

This announcement stands out because it moves beyond ecosystem building and into the development of future therapies.

Mammoth Biosciences was co-founded by Nobel Prize-winning scientist Jennifer Doudna, whose pioneering work helped bring CRISPR gene-editing technology into medicine. Under the agreement, Mammoth will contribute its proprietary gene-editing platform, M42 will provide genomics, health, and clinical research infrastructure, and the Department of Health will support the regulatory and research environment needed to advance development.

The collaboration includes plans to introduce Mammoth’s lead clinical candidate, MB-111, into Abu Dhabi’s research ecosystem, support advanced gene-editing clinical trials, establish advanced therapy manufacturing capabilities, and develop local expertise through workforce training programs.

Perhaps most significantly, the partnership highlights how Abu Dhabi is leveraging its genomics investments. The Emirati Genome Program has created one of the world’s most comprehensive population genomics initiatives. The Mammoth agreement represents an effort to translate those insights into therapies targeting inherited diseases.

As H.E. Dr. Noura Al Ghaithi noted when announcing the partnership, Abu Dhabi is focused on translating genomic insights into therapies to address some of the most complex inherited diseases affecting populations in the region and worldwide.

Leadership Matters

The prominence of Abu Dhabi at BIO 2026 reflects sustained engagement from senior leaders. H.E. Dr. Noura Khamis Al Ghaithi, Undersecretary of the Department of Health – Abu Dhabi, and Dr. Mohamed Al Ameri, Division Director of Genome and Biobank at DoH, are among the officials representing the Emirate’s vision throughout the convention.

Their participation reflects a broader commitment. During Abu Dhabi’s 2025 strategic mission to the United States, approximately 40 representatives from 12 organizations attended more than 20 strategic meetings, conducted 16 institutional visits, participated in 9 BIO-related panels, and established 7 new partnerships and agreements.

Such activity underscores an important point. Building a biotechnology ecosystem requires more than investment capital. It requires leadership, patience, and a willingness to build relationships across borders and disciplines.

A Must-Watch Innovation Hub

For decades, discussions about biotechnology leadership have focused on a familiar collection of cities and regions. Boston, San Diego, Basel, London, and Singapore earned their positions through scientific excellence, entrepreneurial activity, and investment.

Abu Dhabi is pursuing a different path.

The Emirate is leveraging capital, scientific infrastructure, genomics, artificial intelligence, policy support, and international partnerships to establish a presence in the global biotechnology landscape. Its strategy recognizes that modern biotechnology advances through collaboration and that scientific leadership increasingly depends upon connecting talent, expertise, and resources across borders.

BIO 2026 demonstrated that Abu Dhabi is no longer simply expressing an ambition to participate in the life sciences sector. Through initiatives such as the HELM Cluster, partnerships with organizations including Sanofi, Boehringer Ingelheim, Abbott, Biocom California, and Mammoth Biosciences, and investments spanning genomics, research, and advanced therapies, the Emirate is laying the foundations for a biotechnology ecosystem with global aspirations.

Whether Abu Dhabi joins the ranks of the world’s leading life sciences hubs remains to be seen – but it should be watched closely. What is increasingly difficult to overlook is the depth of its commitment and the speed with which effort is being translated into action.

The post Abu Dhabi’s Biotechnology Ambition Comes into Focus at BIO 2026 appeared first on Medika Life.

The body remains, but the self doesn’t.

We understand something in those moments that we rarely say plainly. And perhaps, it’s time we put this idea front and center. Cognition isn’t merely something a person has, it’s something a person is.

Day after day, we become ourselves through the act of thinking. From the complex to the trivial, we traverse a reality that bumps and bruises us into personhood. And that friction isn’t an obstacle to identity, it’s how identity forms.

Aristotle understood this long before neuroscience provided a name for it. Character isn’t something we possess. It is something we create. What we think shapes what we do. What we do, repeatedly, shapes who we become. Which is why the question of artificial intelligence, at least to me, isn’t primarily a question about productivity or efficiency.

Of course, AI doesn’t arrive as a threat, it arrives as a relief. And that’s what makes it so insidious. There’s no cognitive check engine light to warn you. There’s just the comfort of a swift and almost effortless answer. The friction that used to shape you simply didn’t happen. Do that enough times and something changes, not dramatically, but in the way that habits shift things. Gradually, then all at once.

Technology has always extended human capability. The wheel extended our legs. Writing extended memory. The calculator extended arithmetic. But AI is different in kind, and not merely degree. It reaches into cognition itself, into the territory where “we” live—into the domain of judgment, understanding, and idenity. A calculator doesn’t threaten to do your becoming for you.

The neuroscientist Michael Merzenich is well-known for the mechanism that we today call neuroplasticity. Simply put, neural connections are strengthen when used and weakened when not. The brain adapts continuously to the demands placed upon it. This isn’t a lofty metaphor but measurable biology. The brain you exercise is not the brain you don’t.

But cognitive surrender isn’t a neutral act. Every decision handed off to AI are small withdrawals from the account of the self. Of course, handing the process over to a machine provides certain efficiency or even relief, but you step away from the mechanism through which you author, well, you.

There is a phrase, adapted from the Upanishads, that I alluded to earlier: as you think, so you act. As you act, so you become. This is doing more than describing habit. It is describing identity formation. We are not simply what we know. We are, in part, what we have struggled to understand.

The answers may still sound like you. What fills the space is not.

That’s the abyss. Not a dramatic fall, but a quiet retreat from the very process that makes a person a person.

I wrote about the Borrowed Mind as a possibility. Now, I think it’s worth asking, with some regularity, whether it has become a habit.

John Nosta is the author of the best seller:  The Borrow Mind—Reclaiming Human Thought in the Age of AI.

The post AI and the Cognitive Abyss appeared first on Medika Life.

The Exhibition Floor as a Market Signal

However, after several days walking the exhibition floor and listening to discussions across multiple stages, another story emerged. The most interesting development at HLTH Europe was not the continued rise of AI. It was the growing number of companies applying artificial intelligence to solve very specific challenges faced by researchers, physicians, health systems and patients.

What appears on the stages and exhibition floor at HLTH often reflects where the market sees opportunity. Conferences do not create trends. They reveal them. HLTH Europe brought together more than 400 speakers, some 350 sponsors and approximately 5,000 participants from across the global health ecosystem. Artificial intelligence was not simply one topic among many. The conference featured a dedicated AI @ HLTH Zone, AI-focused exhibitors and numerous sessions exploring implementation, governance, clinical applications and operational adoption.

The prominence of AI across both the agenda and exhibition hall was revealing. Conference organizers dedicate space and programming to topics that matter to attendees, investors and sponsors. The visibility of AI at HLTH Europe suggested that health-specific applications of artificial intelligence have moved beyond emerging interest and are now a significant market focus.

That shift matters because health has always demanded more than technological capability. New tools must operate within environments where privacy, safety, accountability and trust are essential. Researchers are looking for ways to accelerate discovery. Physicians want to reduce administrative burdens that consume valuable time. Health systems seek efficiencies that improve operations without compromising quality. Increasingly, innovators are designing AI solutions around those specific needs.

That reality helps explain why many of the most compelling AI companies at HLTH Europe are building solutions specifically for health rather than adapting tools designed for other industries.

As Sophie Taylor-Roberts, managing partner and FINN Partners UK Health Group Lead, shared: “A mistake in healthcare carries a human cost: it can literally mean life or death. That’s why healthcare needs bespoke AI models, tools and solutions that allow for diverse patient populations, differing clinical guidelines, funding and regulatory structures.”

She added, “As with all aspects of health, one size doesn’t fit all. AI must be treated like a highly specialized medical instrument, built to respect national sovereignty, multilingual patient care, and absolute data privacy.”

Health-Specific AI Moves from Possibility to Practice

The trend was visible throughout the exhibition hall, where companies focused on clinical research, physician workflow, diagnostics, patient engagement, digital safety and operational efficiency demonstrated how specialized AI is rapidly becoming a category of its own.

The trend was visible throughout the exhibition hall, where companies focused on clinical research, physician workflow, diagnostics, patient engagement, digital safety and operational efficiency demonstrated how specialized AI is rapidly becoming a category of its own. Their growth reflects a broader shift occurring across the health sector as organizations seek tools designed for specific scientific, clinical and operational challenges.

Gabriele Ricci, Chief Data & Technology Officer at Takeda, captured that evolution when discussing AI’s growing role across the research and development continuum. “AI is transforming the future of healthcare by accelerating every stage of the R&D value chain through purpose-built capabilities tailored to specific scientific and clinical challenges,” he said.

His emphasis on purpose-built capabilities mirrors what was visible throughout HLTH Europe. The conversation is no longer centered exclusively on artificial intelligence as a technology platform. Increasingly, attention is turning toward how specialized applications can address distinct needs across research, clinical care and health operations.

Among the companies reflecting this shift was Briya, whose AI-powered platform helps researchers interact with complex data through conversational interfaces. Rather than requiring users to navigate multiple databases, coding environments and analytical tools, the platform seeks to simplify the path from question to insight.

David Lazerson, Briya’s co-founder and chief executive officer, believes many organizations misunderstand where the greatest challenge in AI adoption resides.

“Many people assume AI adoption is about choosing the right model,” he said. “In reality, the model is only a small part of the solution. The hard part is everything around it: security, governance, data harmonization, domain expertise, and the methodology required to produce trustworthy outcomes.”

His observation reflects a reality becoming increasingly evident throughout the health sector. Access to powerful AI models is expanding rapidly, shifting competitive advantage toward organizations that can generate reliable outcomes within specific health environments. That reality helps explain the growing number of exhibitors focused on narrowly defined use cases rather than general-purpose AI.

A similar perspective emerged from conversations with Keith Grimes, MD, Chief Innovation Officer at Curistica. A physician who spent 24 years in primary care, Grimes approaches artificial intelligence through the lens of risk management, governance and patient safety.

“Physicians have always governed risk,” he explained. “We do it instinctively for doctors, drugs and devices. Digital is just the fourth D, and the discipline is much the same, but it is the one we were never trained for, so the commitment to ‘do no harm’ runs ahead of the know-how.”

His comments address one of the most significant challenges facing health organizations today. Many leaders recognize the promise of AI, yet remain uncertain about implementation, oversight and accountability, particularly in smaller physician practices and community-based care settings.

Dr. Grimes emphasizes that smaller organizations should not view those limitations as barriers.

“Small practices are the cornerstone of primary care, but they cannot out-resource a hospital trust, and it does not need to,” he said. “Good governance scales down, and the same standards that protect a large organization can be borrowed rather than rebuilt.”

“We give whoever is responsible for AI and digital safety both the platform and the people,” Dr. Grimes said. “Power tools that guide them, whatever their experience, with clinical safety experts behind the software.”

Taken together, the perspectives of Dr. Grimes and Lazerson point to the emergence of a new category of innovation. The most promising health AI companies are not focused exclusively on algorithms. They are creating environments that combine technology, expertise and governance to solve specific high-friction problems.

The Future Belongs to Reliable Outcomes

For smaller organizations, this evolution may prove particularly significant. Historically, adopting advanced technology often required substantial investment, specialized technical talent and complex integration efforts. Many health organizations lacked the resources to pursue those initiatives.

Lazerson believes that model is changing. “That’s why we’re seeing the emergence of a new layer of domain-specific AI,” he said. “Instead of every organization hiring AI engineers and building custom infrastructure, they can access a complete, purpose-built environment as a service.”

The implications extend far beyond research organizations. Physician practices, community health providers, home health agencies and emerging life science companies increasingly have access to capabilities that previously required significant internal resources.

“For smaller organizations in particular, it’s a no-brainer,” Lazerson added. “They can start generating value immediately without complex integrations, dedicated AI teams, or having to solve privacy, security, and compliance challenges on their own.”

Throughout HLTH Europe, companies focused on clinical research, workflow automation, diagnostics, care coordination and patient engagement demonstrated how artificial intelligence is becoming increasingly specialized. Rather than attempting to transform every aspect of health simultaneously, they are concentrating on areas where measurable value can be achieved quickly and responsibly.

That focus on practical outcomes may ultimately become the defining characteristic of the next generation of health innovation.

Dr. Grimes summarized the principle succinctly. “Safety is not a box-ticking exercise; it works when everyone knows the part they play,” he said. “The advantage is not scale, it is fit.”

Walking through HLTH Europe, I was reminded that innovation rarely advances through a single breakthrough. More often, progress emerges through focused efforts to solve meaningful problems. The companies attracting attention were helping researchers move faster, supporting clinicians facing administrative burdens and enabling organizations to adopt new capabilities with greater confidence.

Perhaps among the more important lessons from HLTH Europe. The future of AI in health will not be defined solely by the largest platforms. It will be shaped by innovators who combine technology, expertise, and specificity to deliver reliable outcomes. As Lazerson observed, “The future won’t belong to organizations with the biggest models. It will belong to those who can turn AI into reliable outcomes.”

Judging by what appeared across the stages and exhibition floor in Amsterdam, that future is taking shape.

The post At HLTH Europe, the Most Important AI Story Was Happening Beyond the Headlines appeared first on Medika Life.

Despite living longer than men, women spend approximately 25 percent more of their lives in poor health, according to research from the World Economic Forum and the McKinsey Health Institute. Across reproduction, brain health, autoimmune conditions, cardiovascular disease, and mental health, the gaps in research, funding, and care are persistent.

That reality provided important context for the launch of The Shift, a new mini documentary series from BBC StoryWorks Commercial Productions, unveiled at HLTH Europe. The series explores issues ranging from reproductive health and cardiovascular disease to autoimmune disorders, menopause, mental health and healthy aging. Through storytelling, the documentary project elevates the experiences of women while highlighting the challenges that persist and the opportunities for progress.

The HLTH EU panel discussion was timed for the opening of The Shift and featured Shahnoor Abbas, Senior Series Developer and Research Development Lead for The Shift at BBC StoryWorks Commercial Productions; Elena Bonfiglioli, General Manager, Global Health & Life Sciences at Microsoft, and Priya Agrawal, MD, Vice President, Global Health Equity and Partnerships at MSD. Their conversation, moderated by Jody Tropeano Greene, Head of Content for HLTH, explored why women’s health remains one of the most significant opportunities for innovation, investment and system improvement.

A Conversation Decades in the Making

The panelists approached the topic from different perspectives, yet a common theme emerged. Women’s health has received increasing attention for more than a decade, but many of the barriers women encounter remain rooted in the design of health systems.

For BBC StoryWorks, The Shift represents an effort to sustain attention on issues that too often receive episodic interest. The series combines personal stories with broader insights into the realities women face across different countries, cultures and stages of life.

The BBC initiative and the HLTH EU mainstage conversation arrive at a time when women’s health is attracting growing attention from investors, entrepreneurs, policymakers and health industry leaders. New companies are emerging. New technologies are being developed. More organizations are recognizing both the societal and economic importance of addressing longstanding gaps in care.

The timing of The Shift is notable. Women’s health innovation is receiving growing attention from investors, entrepreneurs, policymakers and health leaders. Industry analysts estimate that approximately $2 billion was invested in venture-backed women’s health companies across the United States and Europe in 2025, reflecting increased interest in addressing challenges that extend beyond reproductive health to include cardiovascular disease, menopause, mental health, oncology and healthy aging.

The trend signals growing recognition that improving women’s health is a societal imperative and a significant economic opportunity. Yet as the discussion at HLTH Europe made clear, investment and innovation alone will not be enough if women continue to face fragmented systems that are difficult to navigate.

When Access Exists but Navigation Fails

Dr. Agrawal, an obstetrician-gynecologist by training, whose work has included clinical practice in the UK NHS, global pharma brand stewardship in emerging middle-income nations, maternal health awareness initiatives, and the creation of sustainable health markets, described a reality familiar to many women. Access to care may exist on paper; however, reaching that care, understanding available options and navigating fragmented systems remains a challenge.

“We’ve built systems like mazes with different entry points, different providers and different messages,” said Dr. Agrawal. “Women are often left navigating all of this themselves at the moments where they are most vulnerable.”

Her observation echoed the comments by fellow panelists, which touched on an issue that extends beyond women’s health. Across many countries, patients frequently encounter disconnected providers, inconsistent communication and care journeys that require them to coordinate appointments, referrals and information on their own. The burden of connecting those pieces often falls on the individual seeking care rather than the system intended to support them.

For women, that complexity can be especially challenging. Responsibilities related to caregiving, work, family and personal health often intersect at the very moment care is needed. Understanding what symptoms are normal, knowing when to seek help, determining where to go and finding trusted sources of information become added obstacles.

That reality led to one of the discussion’s compelling observations. “This is not an access problem. It’s a design problem.”

The distinction matters. Discussions about women’s health often focus on whether services exist. Design asks a different question: can people realistically find, understand and benefit from those services when they need them most?

The Power of Stories to Sustain Change

The panel also explored the role technology may play in addressing those challenges. Rather than adding new layers of complexity, emerging digital tools and artificial intelligence applications are increasingly being developed to simplify navigation, improve continuity and support people between clinical encounters.

“What excites me is that technology is finally starting to reduce friction instead of adding layers of complexity,” Dr. Agrawal observed.

That perspective aligned with comments from Bonfiglioli, whose work at Microsoft focuses on helping health systems leverage data, cloud technologies and artificial intelligence to improve outcomes. Technology, however, was not presented as a solution on its own. The discussion repeatedly returned to the importance of human connection.

Those themes are central to the documentary series itself. BBC StoryWorks has built a reputation for transforming complex issues into compelling narratives that audiences can understand and relate to. Through The Shift, the goal is not merely to document challenges but to foster greater understanding of the experiences women face and the opportunities that exist to improve care.

Abbas emphasized the power of storytelling to connect data and lived experience. Statistics can identify a problem. Research can explain it. Stories help people understand why it matters and why action is necessary.

That may be the enduring value of The Shift. The series does not introduce a new conversation. Instead, it brings fresh perspectives to longstanding challenges. Through stories from around the world, the films remind viewers that behind every statistic is a person navigating the complexities of health and care. By fostering greater understanding and empathy, the series encourages health leaders, innovators and policymakers to view women’s health not as a periodic topic of interest, but as an ongoing priority deserving sustained attention and action.

The women featured throughout the series deserve more. The discussion at HLTH Europe reinforces that improving women’s health is more than developing new technologies and expanding services. It is also about creating systems that are easier to navigate, more responsive to people’s medical priorities and ultimately more human in their design.

The post At HLTH Europe, BBC StoryWorks Shines a Light on Women’s Health and the Challenge of Navigating Care appeared first on Medika Life.

What followed feels painfully familiar. Factory owners and industry leaders warned that stronger safety standards, sprinklers, unlocked exits, occupancy limits, and reasonable working hours would cripple American business. Human protection, they argued, was too expensive for the economy to bear.

They were wrong. The tragedy gave rise to the Factory Investigating Commission, the tipping point that led to more than 30 new laws and helped shape the modern American workplace. Today, no serious business leader would argue that unlocked exits, fire escape or basic worker protections weaken the economy. What industry once framed as an unbearable burden became the foundation of responsible business, proving that human safety and long-term productivity, stability, retention, and reputation are inseparable.

We are standing in a similar moment now, and once again, too many leaders are mistaking short-term cost for long-term economic sustainability — the perception of survival.

Today’s equivalent is the belief that purpose, a company’s responsibility to its employees, communities, and environment, is little more than affinity branding. A few lines in the annual report. A polished message for the all-hands staff meeting. Something ornamental rather than operational.

It is the same failure of vision that defined many factory owners in 1911. They saw worker protection as an expense instead of the foundation of a sustainable enterprise. Too many companies still treat sustainability and social responsibility as peripheral to performance, when in reality they are becoming inseparable from resilience, talent retention, operational continuity and customer advocacy. The evidence is growing that this is not simply an ethical argument; it is a business one.

The case also has nothing to do with operating in a “do-good” sector. The 1911 reforms applied to garment factories, foundries and machine shops. Purpose belongs as much to a regional bank, a logistics company, a chip manufacturer, or an ad agency as it does to a B Corp or a clean-energy startup. Every sector employs people, draws on a community, and depends on social and natural systems it did not build, whether or not it markets itself that way.

Consider one number. Gallup’s 2025 State of the Global Workplace report estimates that disengagement costs the world economy roughly $10 trillion in lost productivity each year, a gap equivalent to about 9% of global GDP, while companies with strong recognition and development practices see up to 21% higher profitability. Employee well-being is a direct input to performance on a longer time horizon than the next quarter.

The community piece follows the same logic, and the AI data center boom is the freshest illustration. Residents near new data centers in rural Georgia have reported depleted or contaminated water supplies, and roughly two-thirds of data centers built since 2022 sit in water-stressed regions.

These projects bring construction jobs and tax revenue, but the externalities often fall on the people next door. What happens to their water bills when the aquifer drops? To their home equity when a 200-acre concrete box appears across the road? Or, to the residential electricity rates raised to fund grid upgrades that the data center triggered?

The harder question is how to build in a way that makes the host community better off than before. Operators investing in closed-loop cooling, local water infrastructure, grid upgrades, and tax agreements that share rather than extract value are building a license to operate that will outlast any capex cycle. Over time, brand reputation becomes the cumulative memory of how a company treated the people around it.

Environmental responsibility is the clearest case of all, because the economic vocabulary has finally caught up. Climate exposure is a supply chain risk. Water stress is an operational risk. Biodiversity loss is an input risk. Emissions pose regulatory and capital-cost risks. Companies that dismiss decarbonization as peripheral may be making a similar strategic mistake. Firms that grasped earlier that resilience underwrites profit will outcompete them.

The link between 1911 and 2026 is not philosophical. It is operational. In every era, the responsibilities of business expand to match what we have learned about how value is actually produced, perceived and sustained. Policymakers may argue that expanding employee benefits will ruin the economy. Instead, the economy becomes stronger, employees have greater protection and are more engaged, and the companies that adapt often pull ahead.

A century from now, no one will look back at the companies that invested in their employees’ welfare, treated host communities as partners, and prioritized decarbonization. Few, if any, will call investing in those stakeholder connections a step backward. They will call it what we now call unlocking factory doors: progress, overdue and obvious steps in cementing connections.

In retrospect, societies rarely regret the moments when business broadened its sense of responsibility. We now see protections once dismissed as burdens, like unlocked factory doors and fire escapes, as obvious expressions of human dignity and common sense. Once embraced, it becomes difficult to imagine a world without them.

The post The Fire That Changed American Business appeared first on Medika Life.

A growing body of research is connecting GLP-1 receptor agonists, the class of drugs behind brand names like Ozempic, Wegovy, Mounjaro, and Zepbound, to a serious eye condition that can cause permanent vision loss. The condition has a long medical name: non-arteritic anterior ischemic optic neuropathy, or NAION. Eye specialists sometimes describe it as a stroke of the optic nerve. And once the damage is done, there is currently no treatment that can undo it.

This article is not written to frighten you or push you off your medication without talking to your physician. Millions of people are benefiting from these drugs every day. But the question health experts are now asking out loud is this: when a rare side effect starts appearing in large numbers of people, does it stay rare?

What Are GLP-1 Drugs and Why Are So Many People Taking Them?

GLP-1 stands for glucagon-like peptide-1. These drugs mimic a hormone your gut naturally releases after eating. They slow digestion, reduce hunger, and help control blood sugar. Originally developed for type 2 diabetes, they became household names when studies showed they could also produce significant weight loss.

The popularity of these drugs has been extraordinary. Roughly 15 million people in the United States are currently taking GLP-1 medications, and that number keeps climbing. Many of these users do not have diabetes at all. They are taking the drug specifically to lose weight, often without a full picture of what the long-term risks might look like.

The Eye Condition No One Was Expecting

NAION occurs when blood flow to the front portion of the optic nerve is cut off or severely reduced. The optic nerve is the cable that carries visual signals from your eye to your brain. When that nerve loses its blood supply, even briefly, it can suffer damage that leads to permanent partial or total vision loss in that eye. Health authorities, including the World Health Organization, confirm that this vision loss is usually permanent.

The condition is not brand new. It was already known to affect adults over 50, people with high blood pressure, and people with diabetes. What caught researchers off guard was a cluster of cases appearing in people who had recently started taking semaglutide-based medications.

The alarm was first raised in 2024, when physicians at Massachusetts Eye and Ear, a Harvard Medical School-affiliated hospital, published findings in the journal JAMA Ophthalmology. Their retrospective study of more than 16,000 neuro-ophthalmic patients found that people with type 2 diabetes or obesity who were taking semaglutide had a significantly higher rate of NAION compared to those taking other medications. Among diabetes patients in the study, semaglutide users showed a hazard ratio of 4.28, meaning the risk of developing NAION was more than four times higher than in comparable patients on other glucose-lowering drugs.

A separate Danish and Norwegian study that same year, drawing on data from more than 424,000 patients with type 2 diabetes, found that once-weekly semaglutide use more than doubled the five-year risk of NAION compared to patients taking other diabetes medications.

A Small Percentage Times Millions of People

Here is where the math matters. NAION is classified as “very rare,” meaning it may affect up to 1 in 10,000 people. The European Medicines Agency, which regulates drugs across 27 countries, formally added this classification in June 2025, recommending that product information for Ozempic, Wegovy, and Rybelsus be updated to include NAION as a side effect. The World Health Organization issued its own safety alert shortly after.

But consider what “very rare” actually means when tens of millions of people are taking a drug. If even 1 in 10,000 semaglutide users develops NAION, and 15 million Americans are using GLP-1 medications, that translates to roughly 1,500 potential cases in the United States alone. And that figure is based on the most conservative estimate.

The American Optometric Association’s clinical guidance report put it bluntly: “There is a low risk of serious ocular side effects. But a low risk of a big number is a big risk.”

The University at Buffalo researchers who published a related case series in JAMA Ophthalmology noted something else that raised eyebrows. NAION almost always strikes one eye at a time. But some patients on GLP-1 drugs were presenting with the condition in both eyes simultaneously, which is considered atypical and potentially more alarming.

The Research Is Still Sorting Itself Out

To be fair, the picture is not entirely clear-cut. A large February 2025 retrospective study that pooled data from 37 million diabetes patients across 14 international databases found that semaglutide users showed about 14 to 15 NAION cases per 100,000 patients annually, and when compared to other GLP-1 drugs, the risk was not significantly different. This suggests the vision risk may apply to the entire class of GLP-1 medications, not just semaglutide specifically.

A separate large cohort study published in JAMA Network Open, covering 185,000 individuals on GLP-1 drugs, found a slightly higher risk of developing diabetic retinopathy, but a similar rate of NAION compared to those on other treatments. And two studies presented at the American Academy of Ophthalmology’s 2025 annual meeting offered conflicting signals: one tied GLP-1 drugs to increased NAION risk and diabetic retinopathy risk, while another suggested the drugs might actually protect against dry age-related macular degeneration.

Scientists are careful to note that none of the current evidence proves that GLP-1 drugs cause NAION. What exists is a statistically significant association that has now been observed across multiple studies, multiple countries, and multiple drug databases. That is enough to prompt regulatory bodies to act and researchers to dig deeper.

Who May Be at Highest Risk?

Physicians are paying special attention to patients who already have underlying vascular risk factors. High blood pressure, high cholesterol, diabetes, a history of cardiovascular disease, and a structural eye condition called a small optic disc are all considered risk factors for NAION independent of GLP-1 use. When these pre-existing vulnerabilities are combined with a medication that may affect blood flow to the optic nerve, the potential for harm may be higher.

The symptoms to watch for are specific and sudden: vision loss in one eye that seems to come on without warning, often noticed upon waking. There may be a dark or blurry area in part of your field of vision, or a sense that something has been “wiped away” in one corner of sight. There is typically no pain, which is part of why people sometimes wait before seeking care. Any of these symptoms should be treated as a medical emergency.

Where Things Stand Right Now

As of June 2026, the European Medicines Agency has updated its labeling requirements for semaglutide to include NAION. The World Health Organization has issued a formal safety alert. And a multidistrict litigation involving GLP-1 vision loss lawsuits was consolidated in the Eastern District of Pennsylvania in December 2025. Legal analysts report that over 1,800 lawsuits had been filed by mid-2025, with more expected as scientific review continues.

The U.S. Food and Drug Administration has not yet added a NAION warning to American drug labels for semaglutide. Novo Nordisk, which manufactures Ozempic and Wegovy, has not yet updated its U.S. prescribing information to reflect the risk. Public health advocates and some legal experts have called for a black box warning, the FDA’s highest-level alert.

The American Academy of Ophthalmology and the North American Neuro-Ophthalmology Society have both weighed in, stating that they do not recommend that all semaglutide users stop their medication immediately if they develop NAION, since the benefits of the drug may still outweigh individual risks, depending on the patient’s overall health. But both organizations agree that sudden vision changes of any kind require immediate medical evaluation.

What This Means for You

If you are currently taking a GLP-1 medication for weight loss or diabetes management, here are the most important things to keep in mind.

1. Do not stop your medication without talking to your physician. For many people, the health benefits of these drugs are substantial, and an abrupt stop can create its own risks.
2. Tell your physician if you have existing eye problems, high blood pressure, or a history of cardiovascular disease. These factors may influence how closely you should be monitored.
3. Take sudden vision changes seriously. If you wake up one morning and something looks wrong with one eye, that is not something to wait out. Call your physician or go to an emergency room. Time may matter.
4. Ask questions. Ask your physician whether NAION has been discussed in your care plan. Ask whether your specific risk factors warrant more frequent eye exams. You have the right to that conversation

The Larger Question

GLP-1 medications have been genuinely life-changing for many people. They have helped reduce the burden of obesity, lower cardiovascular risk, and control blood sugar in ways that were difficult to achieve before. None of that is in dispute.

But when a drug reaches the scale of tens of millions of users, even rare side effects become a public health question. A risk that affects fewer than 1 in 10,000 people in a clinical trial still produces thousands of real individuals with real and permanent vision loss when multiplied across the population taking these drugs. Those individuals deserve answers, updated labels, and the chance to make informed decisions before the lights go out.

Research is ongoing. Regulatory conversations are happening. In the meantime, staying informed, staying in communication with your physician, and taking any sudden change in vision seriously are the most important steps you can take.

The post The Weight-Loss Drug Nobody Warned You About: When the Scale Goes Down, and Your Sight Goes With It appeared first on Medika Life.

Bringing Conversational AI to Scientific Research

The announcement arrives as artificial intelligence continues to reshape nearly every corner of the health sector. Much of the attention has focused on applications designed for consumers seeking information or clinicians seeking support in managing increasingly complex workloads. Briya is directing its attention to a different priority audience: medical researchers in academia, hospitals and life science companies.

The decision reflects a recognition that scientific inquiry often remains constrained by barriers that have little to do with science itself. Researchers routinely navigate fragmented data sources, technical requirements, analytical platforms and resource limitations before they can begin testing a hypothesis or exploring an observation.

The Next Step in Briya’s Evolution

Briya is executing on the established understanding that artificial intelligence can help reduce those barriers.

Researchers using AIRE will be able to explore public health information, including data from the U.S. Centers for Disease Control and Prevention, through a browser-based conversational interface. Rather than writing code, users can ask questions in natural language, refine their inquiry through dialogue and review the analytical pathway used to produce results.

“The last few years proved that AI can generate answers,” Briya co-founder and CEO David Lazerson told Medika Life. “The next challenge is making AI capable of generating trustworthy science. That requires a fundamental shift from general-purpose AI systems to research environments built around transparency, epidemiological methodology and scientific accountability.”

The announcement represents the latest step in Briya’s evolution. Founded in 2020 by Lazerson and Chief Technology Officer Guy Tish, the company initially centered efforts on helping organizations connect fragmented health data while maintaining privacy protections, governance requirements and institutional control over sensitive information.

Medical records rarely exist in a single location. Information is often distributed across electronic medical records, laboratory systems, imaging platforms, physician notes and institutional databases. Briya developed a federated approach that allows information to remain within source organizations while supporting approved research across participating data environments.

AIRE expands that mission from data access to data exploration.

The platform is designed to support cohort construction, endpoint validation, treatment pathway analysis, chart review and the exploration of structured and unstructured clinical information. Researchers interact with the platform through conversation rather than code, allowing them to start with a scientific question rather than a technical workflow.

The strategy mirrors an approach that has proven successful in other areas of artificial intelligence. Consumer platforms such as ChatGPT and Perplexity accelerated adoption by allowing users to experience the value of AI before deciding whether additional capabilities justified a subscription.

Reducing the Distance Between Questions and Answers

Briya is applying a similar philosophy to research. Many health technology companies continue to pursue adoption through enterprise purchasing processes, institutional pilots and lengthy implementation cycles. The Briya approach places the researcher at the center of the experience and allows investigators to determine the platform’s value through direct, frequent use.

The company believes that approach may be particularly meaningful for researchers working outside large academic medical centers and major pharmaceutical companies. Those institutions often have access to dedicated data science teams and sophisticated analytical resources. Smaller universities, physician-scientists, public health investigators and community-based researchers may not.

The absence of resources does not diminish the importance of the questions they seek to answer. In fact, as many attending HLTH EU head from Amsterdam to BIO International in San Diego, many of the biggest life-changing advances start in smaller research settings.

Giving Researchers a Seat at the Table

A physician observing an unusual treatment response, a public health researcher investigating a local health pattern, or an early-career investigator evaluating a new hypothesis all face the same challenge: transforming observation into evidence. That process frequently requires technical expertise and infrastructure that are not universally available.

Reducing those barriers could expand participation in research and potentially broaden the range of questions being explored. Accessibility alone, however, is not enough.

Scientific inquiry requires transparency, reproducibility and methodological rigor. Researchers must understand how conclusions are reached, what assumptions influence an analysis and where potential bias may exist.

A Move from Observation to Evidence

Recognizing those requirements, Briya recently appointed internationally recognized epidemiologist Professor Jonathan Samet, MD, MS, as Chief Epidemiologist. Dr. Samet is Professor of Epidemiology and Occupational and Environmental Health, and the former Dean of the Colorado School of Public Health.

“Scientific rigor and accountability cannot be layered onto AI after the fact,” Dr. Samet told Medika Life. “If these technologies are going to play a meaningful role in healthcare research, transparency, reproducibility and epidemiological methodology must be built directly into the system itself.”

Samet added that researchers need to understand more than an AI-generated conclusion: “Researchers need to understand not only what an AI system concludes, but how it reached those conclusions and what risks may exist along the way.”

His appointment reflects a broader challenge facing artificial intelligence in research environments. While generative AI systems can produce clear and persuasive responses, researchers and institutions must be able to evaluate the methods, assumptions and analytical pathways behind those outputs.

Trust, governance and cybersecurity have become as important as speed and convenience. Health information remains among the most sensitive categories of personal data. Institutions considering AI-enabled research environments must evaluate privacy protections, security controls and governance requirements alongside scientific capabilities.

Briya says its architecture is designed to allow data to remain within source organizations while supporting anonymization, compliance controls and auditable pathways for approved analysis.

Briya’s decision to open access to AIRE arrives at a time when researchers are under increasing pressure to produce meaningful scientific output while navigating growing volumes of health information. The platform’s no-cost entry point reflects a broader shift occurring across technology, where organizations increasingly recognize that adoption begins with customer experience. By allowing researchers to engage directly with data through a conversational interface, Briya is reducing barriers that have traditionally separated scientific questions from scientific exploration and adoption.

The announcement broadens the conversation surrounding artificial intelligence in health. Much of the industry’s attention has focused on consumer and clinical applications. Briya is directing attention to another critical constituency whose work influences every future therapy, diagnostic and public health intervention.

As HLTH Europe begins, the company is making the case that empowering researchers may represent one of the most consequential applications of artificial intelligence in health. If successful, the approach could help accelerate discovery, expand participation in research and provide investigators with a direct path from observation to evidence to implementation.

The post At HLTH Europe, Briya Opens No-Cost Access to AI-Powered Research appeared first on Medika Life.